

Laboratory Service Report

1-800-533-1710

Patient Name SAMPLEREPORT,COMT	Patient ID 0000180807	Age 46	Gender F	Order # 0000180807
Ordering Phys			I	DOB 06/10/1966
Client Order # 0000180807	Account Information			Report Notes
Collected 03/14/2013 23:39	C7028846-DLMP Rochester 3050 Superior Drive			
Printed 05/23/2013 11:33	Rochester, MN 55901			

Test	Flag	Results	Unit	Reference Value	Perform Site*
			REPORTED 05	/22/2013 14:45	
Homozygous COMT*1/*1. Thi the COMT*1 normal allele a encoding enzyme with norma defined as normal and is a metabolizer phenotype. Direct polymorphism analys performed following PCR an will not detect all the kr decreased or inactive COMT mutation or polymorphism of that a patient has an inter phenotype. Patients with metabolizer genotype may F inhibited by a variety of metabolites. The following known to affect COMT active report.	pe is individual and has two co al activity. associated wit sis for 472G>A mplification. nown mutations f. Absence of does not rule ermediate or p an extensive nave COMT enzy medications, g is a partial vity as of the	is homozygous for opies of the gene This genotype is th the extensive A and 304G>A is Direct DNA testing s that result in a detectable gene out the possibility poor metabolizer or intermediate yme activity or their l listing of drugs e date of this			MCK
Drugs that undergo metabol DOPA,Apomorphine, Benseraz Dihydroxyphenylserine, Dok 2-Hydroxyestrogens, 4-Hydr Isoprenaline, Isoproterena Co-administration may decr other drugs metabolized by	lism by COMT: zide, Bitolter putamine, Dopa coxyestogens, al, Norepineph rease the rate y COMT.	Alpha-methyl rol, amine, Epinephrine, Isoetherine, nrine, Rimiterol. e of elimination of			
Structurally modified drug COMT: Albuterol, Metaprot Phenylephrine, Perbuterol, will not decrease the rate COMT.	gs that are no cerenol, Metho , Terbutaline. e of metabolis	ot metabolized by oxamine, . Co-administration sm of other drugs by			
Drugs known to inhibit COM Tolcapone, Nitecapone. Die activity: Quercetin, Tea o decrease the rate of metak increasing the possibility heterozygous individuals. Laboratory developed test.	MT activity: etary Componer catechins. Co- colism of COMT y of toxicity,	Entacapone, hts that inhibit COMT -administration will F metabolized drugs, , including			
Reviewed by		Jennifer Herman			MCR

Performing Site Legend on Last Page of Report

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,COMT	03/14/2013 23:39	Final
Page 1 of 2		>> Continued on Next Page >>

* Report times for Mayo performed tests are CST/CDT



Laboratory Service Report

1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,COMT	0000180807	46	F	0000180807
Ordering Phys				DOB
				06/10/1966
Client Order #	Account Information			Report Notes
0000180807				
Collected	C7028846-DLMP Rochester			
03/14/2013 23:39	3050 Superior Drive			
Printed	Rochester, MN 55901			
05/23/2013 11:33				

			Reference	Perform
Test	Flag Results	Unit	Value	Site*

>> Accession 0000180807 - Continued From Previous Page << >> Do Not Discard <<</pre>

* Performing Site:

	MCR Ma 20	ayo Clinic Laboratories - Rochester Main Campus 00 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
--	--------------	---	--

Patient Name SAMPLEREPORT,COMT	Collection Date and Time 03/14/2013 23:39	Report Status Final
Page 2 of 2		** End of Report **

* Report times for Mayo performed tests are CST/CDT